JP2016527279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527279A5 JP2016527279A5 JP2016531940A JP2016531940A JP2016527279A5 JP 2016527279 A5 JP2016527279 A5 JP 2016527279A5 JP 2016531940 A JP2016531940 A JP 2016531940A JP 2016531940 A JP2016531940 A JP 2016531940A JP 2016527279 A5 JP2016527279 A5 JP 2016527279A5
- Authority
- JP
- Japan
- Prior art keywords
- trifluoromethyl
- amino
- pyridin
- use according
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 21
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 21
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 20
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 15
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 13
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 10
- 108700028369 Alleles Proteins 0.000 claims description 7
- 206010008583 Chloroma Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 201000005987 myeloid sarcoma Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- 238000000634 powder X-ray diffraction Methods 0.000 claims 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 14
- 239000013078 crystal Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 201000005787 hematologic cancer Diseases 0.000 claims 8
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 7
- 230000000750 progressive effect Effects 0.000 claims 7
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 6
- URUBZXVIOILFLM-UHFFFAOYSA-N CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O Chemical compound CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O URUBZXVIOILFLM-UHFFFAOYSA-N 0.000 claims 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 5
- 239000012458 free base Substances 0.000 claims 5
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims 4
- 239000006186 oral dosage form Substances 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- SWWHCQCMVCPLEQ-UHFFFAOYSA-N propan-2-yl methanesulfonate Chemical compound CC(C)OS(C)(=O)=O SWWHCQCMVCPLEQ-UHFFFAOYSA-N 0.000 claims 2
- -1 4- [ 6- (Trifluoromethyl) pyridin-2-yl] -6-{[2- (trifluoromethyl) pyridin-4-yl] amino} -1,3,5-triazin-2-yl Chemical group 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 description 26
- 230000000694 effects Effects 0.000 description 5
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861884P | 2013-08-02 | 2013-08-02 | |
| US61/861,884 | 2013-08-02 | ||
| PCT/CN2013/081170 WO2015018060A1 (en) | 2013-08-09 | 2013-08-09 | Crystalline forms of therapeutically active compounds and use thereof |
| CNPCT/CN2013/081170 | 2013-08-09 | ||
| US201461939098P | 2014-02-12 | 2014-02-12 | |
| US61/939,098 | 2014-02-12 | ||
| US201461975448P | 2014-04-04 | 2014-04-04 | |
| US61/975,448 | 2014-04-04 | ||
| US201462011948P | 2014-06-13 | 2014-06-13 | |
| US62/011,948 | 2014-06-13 | ||
| PCT/US2014/049469 WO2015017821A2 (en) | 2013-08-02 | 2014-08-01 | Therapeutically active compounds and their methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019082794A Division JP2019142930A (ja) | 2013-08-02 | 2019-04-24 | 治療活性のある化合物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527279A JP2016527279A (ja) | 2016-09-08 |
| JP2016527279A5 true JP2016527279A5 (enExample) | 2017-09-07 |
| JP6742905B2 JP6742905B2 (ja) | 2020-08-19 |
Family
ID=52432592
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531940A Active JP6742905B2 (ja) | 2013-08-02 | 2014-08-01 | 治療活性のある化合物及びその使用方法 |
| JP2019082794A Withdrawn JP2019142930A (ja) | 2013-08-02 | 2019-04-24 | 治療活性のある化合物及びその使用方法 |
| JP2021123814A Pending JP2021176893A (ja) | 2013-08-02 | 2021-07-29 | 治療活性のある化合物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019082794A Withdrawn JP2019142930A (ja) | 2013-08-02 | 2019-04-24 | 治療活性のある化合物及びその使用方法 |
| JP2021123814A Pending JP2021176893A (ja) | 2013-08-02 | 2021-07-29 | 治療活性のある化合物及びその使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US9738625B2 (enExample) |
| EP (3) | EP3027193A4 (enExample) |
| JP (3) | JP6742905B2 (enExample) |
| CN (3) | CN110372670B (enExample) |
| AU (2) | AU2014295938B2 (enExample) |
| BR (1) | BR112016002287A2 (enExample) |
| CA (1) | CA2919382A1 (enExample) |
| CL (2) | CL2016000263A1 (enExample) |
| EA (1) | EA030428B1 (enExample) |
| ES (1) | ES2886211T3 (enExample) |
| IL (2) | IL243833A0 (enExample) |
| MX (2) | MX389250B (enExample) |
| MY (1) | MY177994A (enExample) |
| NI (1) | NI201600022A (enExample) |
| PE (1) | PE20160840A1 (enExample) |
| PH (1) | PH12016500164B1 (enExample) |
| SA (1) | SA516370523B1 (enExample) |
| SG (2) | SG11201600479WA (enExample) |
| TW (2) | TWI666208B (enExample) |
| UA (1) | UA121021C2 (enExample) |
| WO (1) | WO2015017821A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015017821A2 (en) * | 2013-08-02 | 2015-02-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3200800A1 (en) * | 2014-09-29 | 2017-08-09 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20180134683A1 (en) * | 2015-05-07 | 2018-05-17 | Teligene Ltd. | Heterocylcic compounds as idh2 inhibitors |
| WO2017016513A1 (zh) | 2015-07-30 | 2017-02-02 | 正大天晴药业集团股份有限公司 | 1,3,5-三嗪衍生物及其使用方法 |
| EP3331866B1 (en) | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
| CA3001599A1 (en) | 2015-10-15 | 2017-04-20 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| MX381582B (es) * | 2015-10-15 | 2025-03-12 | Celgene Corp | Terapia de combinacion para el tratamiento de neoplasias malignas. |
| JP6588647B2 (ja) * | 2015-10-21 | 2019-10-09 | ノイフォルム・ファーマシューティカルズ・インコーポレイテッドＮｅｕｆｏｒｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 血液悪性腫瘍を治療するための重水素化合物及びその組成物並びに方法 |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| WO2017146795A1 (en) * | 2016-02-26 | 2017-08-31 | Agios Pharmaceuticals, Inc. | Idh1 inhibitors for the treatment of haematological malignancies and solid tumours |
| US20180042930A1 (en) | 2016-08-03 | 2018-02-15 | Celgene Corporation | Methods of treatment of malignancies |
| JP7093764B2 (ja) * | 2016-08-03 | 2022-06-30 | セルジーン コーポレイション | 骨髄異形成症候群の治療方法 |
| JP2019529534A (ja) | 2016-09-07 | 2019-10-17 | セルジーン コーポレイション | 錠剤組成物 |
| CN113549056A (zh) | 2017-01-22 | 2021-10-26 | 正大天晴药业集团股份有限公司 | 1,3,5-三嗪衍生物的盐及其晶体、它们的制备方法、药物组合物和用途 |
| EP3618828B1 (en) | 2017-05-05 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| PL3644999T3 (pl) | 2017-06-30 | 2023-05-08 | Celgene Corporation | Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| US20220017489A1 (en) | 2018-11-02 | 2022-01-20 | Celgene Corporation | Solid dispersions for treatment of cancer |
| US20220017490A1 (en) | 2018-11-02 | 2022-01-20 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| US12215094B2 (en) * | 2018-11-02 | 2025-02-04 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| CN114773320A (zh) * | 2022-05-29 | 2022-07-22 | 重庆医科大学 | 1,3,5-三嗪化合物及其制备方法和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390529A (en) | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
| JPS58186682A (ja) | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
| DE3512630A1 (de) | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
| ATE130882T1 (de) | 1990-07-12 | 1995-12-15 | Ciba Geigy Ag | Verfahren zur photochemischen und thermischen stabilisierung von polyamid-fasermaterialien. |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| EP1187825A1 (en) | 1999-06-07 | 2002-03-20 | Shire Biochem Inc. | Thiophene integrin inhibitors |
| WO2003037346A1 (en) * | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
| HUE029020T2 (en) | 2002-07-18 | 2017-02-28 | Janssen Pharmaceutica Nv | Substituted triazine kinase inhibitors |
| EP2152676B1 (en) * | 2007-04-30 | 2013-04-03 | ProMetic BioSciences Inc. | "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives" |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| US20120238576A1 (en) * | 2009-06-08 | 2012-09-20 | California Capital Equity, Llc | Triazine Derivatives and their Therapeutical Applications |
| US8486939B2 (en) * | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| LT2800743T (lt) | 2012-01-06 | 2018-06-25 | Agios Pharmaceuticals, Inc. | Terapiškai aktyvūs junginiai ir jų panaudojimo būdai |
| CN104169260A (zh) | 2012-03-09 | 2014-11-26 | 卡尔那生物科学株式会社 | 新三嗪衍生物 |
| ES2807582T3 (es) | 2013-07-11 | 2021-02-23 | Agios Pharmaceuticals Inc | Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015017821A2 (en) * | 2013-08-02 | 2015-02-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3200800A1 (en) | 2014-09-29 | 2017-08-09 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
-
2014
- 2014-08-01 WO PCT/US2014/049469 patent/WO2015017821A2/en not_active Ceased
- 2014-08-01 PE PE2016000214A patent/PE20160840A1/es not_active Application Discontinuation
- 2014-08-01 PH PH1/2016/500164A patent/PH12016500164B1/en unknown
- 2014-08-01 EA EA201690322A patent/EA030428B1/ru not_active IP Right Cessation
- 2014-08-01 EP EP14832505.3A patent/EP3027193A4/en not_active Withdrawn
- 2014-08-01 US US14/909,451 patent/US9738625B2/en active Active
- 2014-08-01 BR BR112016002287A patent/BR112016002287A2/pt not_active Application Discontinuation
- 2014-08-01 MY MYPI2016700311A patent/MY177994A/en unknown
- 2014-08-01 MX MX2016001361A patent/MX389250B/es unknown
- 2014-08-01 EP EP21178745.2A patent/EP3932408A1/en not_active Withdrawn
- 2014-08-01 CA CA2919382A patent/CA2919382A1/en not_active Abandoned
- 2014-08-01 ES ES19177845T patent/ES2886211T3/es active Active
- 2014-08-01 JP JP2016531940A patent/JP6742905B2/ja active Active
- 2014-08-01 TW TW103126335A patent/TWI666208B/zh active
- 2014-08-01 TW TW108110624A patent/TWI701242B/zh active
- 2014-08-01 UA UAA201601999A patent/UA121021C2/uk unknown
- 2014-08-01 CN CN201910707312.9A patent/CN110372670B/zh active Active
- 2014-08-01 CN CN201910708167.6A patent/CN110386922A/zh active Pending
- 2014-08-01 SG SG11201600479WA patent/SG11201600479WA/en unknown
- 2014-08-01 MX MX2020011397A patent/MX394658B/es unknown
- 2014-08-01 CN CN201480053796.5A patent/CN105916507A/zh active Pending
- 2014-08-01 AU AU2014295938A patent/AU2014295938B2/en active Active
- 2014-08-01 EP EP19177845.5A patent/EP3566706B1/en active Active
- 2014-08-01 SG SG10201709187TA patent/SG10201709187TA/en unknown
-
2016
- 2016-01-28 IL IL243833A patent/IL243833A0/en unknown
- 2016-02-01 SA SA516370523A patent/SA516370523B1/ar unknown
- 2016-02-01 NI NI201600022A patent/NI201600022A/es unknown
- 2016-02-02 CL CL2016000263A patent/CL2016000263A1/es unknown
-
2017
- 2017-07-13 US US15/649,551 patent/US10093654B2/en active Active
- 2017-09-04 CL CL2017002240A patent/CL2017002240A1/es unknown
-
2018
- 2018-09-04 US US16/121,483 patent/US10730854B2/en active Active
- 2018-10-10 AU AU2018247242A patent/AU2018247242B2/en active Active
-
2019
- 2019-04-24 JP JP2019082794A patent/JP2019142930A/ja not_active Withdrawn
- 2019-10-31 IL IL270347A patent/IL270347B/en unknown
-
2020
- 2020-06-29 US US16/915,936 patent/US20210155603A1/en not_active Abandoned
-
2021
- 2021-07-29 JP JP2021123814A patent/JP2021176893A/ja active Pending
-
2023
- 2023-05-08 US US18/144,695 patent/US20240132474A1/en not_active Abandoned
-
2025
- 2025-05-07 US US19/201,790 patent/US20260085059A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021176893A5 (enExample) | ||
| Lim et al. | Is targeting autophagy mechanism in cancer a good approach? The possible double-edge sword effect | |
| JP2018504429A5 (enExample) | ||
| WO2017200016A1 (ja) | Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬 | |
| CN103565653B (zh) | 取代的吡唑酮化合物及其使用方法和用途 | |
| KR20140043314A (ko) | 이중 오로라 키나제／ｍｅｋ 억제제를 사용한 항암 치료법 | |
| JP2019513694A5 (enExample) | ||
| JP2019533670A5 (enExample) | ||
| JP2019502669A5 (enExample) | ||
| AU2014208964B2 (en) | Chemical compounds | |
| WO2013112950A3 (en) | Certain chemical entities, compositions, and methods | |
| EP4452256B1 (en) | Methods of treating brain tumours and neuroblastomas | |
| TW201332548A (zh) | 用於治療慢性骨髓性白血病之ｎ－甲基－２－〔３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基〕－苯甲醯胺 | |
| Schneider et al. | Phase II Trial of Imatinib Maintenance Therapy After Irinotecan and Cisplatin in Patients With c-Kit–Positive, Extensive-Stage Small-Cell Lung Cancer | |
| Noonan et al. | Targeting autophagy in glioblastoma | |
| CN109641890A (zh) | 异柠檬酸脱氢酶(idh)抑制剂 | |
| Ho et al. | Cancer Management by Tyrosine Kinase Inhibitors: Efficacy | |
| AU2021229457A1 (en) | Therapeutic uses of macrocyclic compounds | |
| RU2747644C2 (ru) | Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака | |
| US20180112258A1 (en) | Medical uses and methods for treating cancer using monopolar spindle 1 (mps1) kinase inhibitors | |
| US20220281859A1 (en) | Heterocyclic compounds as kinase inhibitors | |
| Jiang et al. | Recent advances in Pyrazolo [3, 4-d] pyrimidine-based dual inhibitors in the treatment of cancers | |
| Osman et al. | Epigenetic modulation in oncology: in-silico mechanistic studies of emerging enhancer zeste of homolog 2 inhibitors | |
| Demuth et al. | Novel Pharmacological Approaches to Target Mitochondrial Metabolism and DNA Damage Response in Colorectal Cancer and their Synergism with Established Chemotherapeutics | |
| Voon et al. | The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer |